Gene Solutions Thailand Exhibition & Symposium Highlight at TSCO Annual Meeting

Explore the highlights from our booth exhibition and symposium at the Thai Society of Clinical Oncology (TSCO) Annual Meeting, held from October 18-20, 2024, at Dusit Thani Pattaya, Thailand.

Gene Solutions team at the TSCO Annual Meeting 2024 exhibition booth showcasing ctDNA, Minimal Residual Disease (MRD), and precision oncology applications, attended by Thai Society of Clinical Oncology members and professionals in cancer research.

During Symposium 3, Gene Solutions presented an insightful session featuring Professor Nick Pavlakis from the University of Sydney and Dr. Tu Ngoc Ly Lan from the Medical Genetics Institute HCMC. They shared groundbreaking applications of Minimal Residual Disease (MRD) and discussed global clinical trials, showcasing the rapid advancements in circulating tumor DNA (ctDNA)-based testing.

Professor Pavlakis comprehensively reviewed all current aspects of ctDNA MRD, from technical approaches to clinical applications. In terms of technical strategies, he discussed two notable subjects: proven enrichment strategies using Hybridization Capture (NGS) or Multiplex PCR Amplification (NGS) to increase ctDNA sensitivity, and technical classifications to identify Clonal Hematopoiesis of Indeterminate Potential (CHIP), which has a mutational frequency of approximately 92% in 60-year-olds and can cause false positives.

Professor Nick Pavlakis discusses the applications of ctDNA in monitoring Minimal Residual Disease (MRD) at the TSCO Annual Meeting 2024, highlighting advances in lung and colorectal cancer treatment

In clinical applications, Professor Pavlakis highlighted multiple studies that provided compelling evidence of MRD:

  • Applications of ctDNA assay for MRD in early-stage curatively treated cancers: These applications vary from peri-operative prognostic and predictive uses, including escalation of adjuvant therapy (MRD+) in lung cancer, de-escalation/avoidance of adjuvant therapy (MRD-) in colorectal cancer, and surveillance/monitoring for recurrence.
  • One study in resected EGFRm stage IB-IIIA NSCLC: This study showed that patients receiving adjuvant osimertinib were more likely to be DFS and MRD event-free compared to those receiving a placebo.
  • One study in neoadjuvant chemotherapy in TNBC: ctDNA dynamics during neoadjuvant chemotherapy showed evidence in predicting clinical outcomes.
  • One recent study in CRC demonstrated that a ctDNA-informed approach to adjuvant therapy selection in stage II colon cancer can reduce chemotherapy use without compromising survival rates.

Dr. Tu Ngoc Ly Lan of Gene Solutions presents on genomic profiling and personalized cancer monitoring at the TSCO Annual Meeting 2024, focusing on the benefits of ctDNA-based monitoring

Dr. Tu Ngoc Ly Lan provided another perspective on current MRD methods, discussing the advantages and limitations of ctDNA and how to interpret its results. While it is widely acknowledged that ctDNA is more sensitive than conventional biomarkers and imaging in multiple cancers, she emphasized that no test detects ctDNA in 100% of cases. Detection rates can vary based on assay sensitivity, sample quality, and tumor location, particularly in cases with low ctDNA shedding, such as breast luminal cancer, lung adenocarcinoma, or metastatic sites in the brain, bone, and peritoneum.

The insights shared by the two experts enriched the audience’s overview of MRD, highlighting high-sensitivity methods and their application in clinical practice.

Symposium 3 at the TSCO Annual Meeting 2024 featuring discussions on ctDNA's role in monitoring Minimal Residual Disease, with speakers Dr. Tu Ngoc Ly Lan and Professor Nick Pavlakis

We deeply appreciate the organizers, moderators, speakers, and medical oncologists who participated in this cutting-edge sharing for the sake of better personalized cancer care.

#ctDNA #MRD # PrecisionOncology #Personalizedmonitoring #TSCO

LATEST News

ESMO 2026 Gene Solutions Global Industry Satellite Symposium AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

MADRID, Nov. 18, 2026 — Gene Solutions hosted its first Global Industry Satellite Symposium, sharing multi-omic liquid biopsy technologies and the clinical and real-world data generated in Asia with the international oncology community. The achievement reflects the company’s evolution from an Asia-based genetic testing pioneer to a globally engaged innovator of cell-free DNA technologies span ning cancer screening, precision oncology, and functional applications.     ESMO Congress, one of the world’s leading oncology meetings, brought together more than 40,000 participants from the global cancer community in Madrid in 2026 for the largest congress in ESMO’s history. The meeting provided a

Read More
Panel Discussion​ | Bridging Regional Evidence to Global Precision Oncology: Challenges and Opportunities in Multi-Omic Liquid Biopsy Implementation Across the Cancer Care Continuum ESMO 2026 Gene Solutions

Inside Gene Solutions’ ESMO 2026 Symposium and Scientific Program: Six Perspectives Across the Cancer Care Continuum

At ESMO Congress 2026 in Madrid, Gene Solutions hosted its first Industry Satellite Symposium at the main ESMO Congress, bringing clinical validation, real-world experience, and multi-omic innovation generated in Asia into the global oncology conversation.  The full-house symposium, “AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation,” brought together six international faculty members to share scientific and clinical perspectives on the future of cancer detection and precision oncology.  Co-chaired by Prof. Umberto Malapelle of the University of Naples Federico II and Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong,

Read More
New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More